Ernexa Therapeutics Highlights Key Catalysts as Company Advances Toward First-in-Human Clinical Trials in 2026

Core Insights - Ernexa Therapeutics is advancing its lead product candidate ERNA-101 towards a first-in-human clinical trial for platinum-resistant ovarian cancer, with an IND submission expected in Q3 2026 and trial initiation planned for Q4 2026 [1][2][14] - The company has reported significant preclinical data showing durable tumor regressions and prolonged survival in ovarian cancer models when ERNA-101 is combined with PD-1 blockade, indicating its potential as a foundational immunotherapy platform [3][8] - Ernexa is also developing ERNA-201, an engineered anti-inflammatory therapy targeting autoimmune diseases, alongside the advancement of ERNA-101 [5][12] Company Progress - Ernexa has streamlined operations, reducing general and administrative expenses by approximately 61% year over year while maintaining focus on core programs [9] - The company completed Proof of Principle studies for both ERNA-101 and ERNA-201 and successfully held a Pre-IND meeting with the FDA for ERNA-101 [9][10] Upcoming Milestones - Key milestones include the completion of ERNA-101 clinical manufacturing process development in Q2 2026, IND-enabling preclinical studies in Q3 2026, and the initiation of the first-in-human Phase 1 clinical study in Q4 2026 [14] - Initial clinical data readout from ERNA-101 is expected in the first half of 2027, with advancement into Phase 2 trials anticipated in the second half of 2027 [14]